Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV

Arianna E. Kousaria Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USAView further author information

Melissa P. Wilsona Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USAView further author information

Kellie L. Hawkinsa Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA;b Denver Health and Hospital Authority, Denver, CO, USAView further author information

Mohamed Mehdi Bandalic School of Medicine, University of Colorado, Aurora, CO, USAView further author information

Andrés F. Henao-Martíneza Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USAView further author information

Edward M. Gardnera Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA;b Denver Health and Hospital Authority, Denver, CO, USAView further author information

Kristine M. Erlandsona Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USACorrespondence[email protected]

https://orcid.org/0000-0003-0808-6729 View further author information

show all

Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date